Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia

Circulation

Volumn 100, Issue 6, 1999, Pages 587-593

  Greinacher, Andreas ^a   Janssens, Uwe ^b   Berg, Gunther ^c   Böck, Markus ^d   Kwasny, Harald ^e   Kemkes Matthes, Bettina ^f   Eichler, Petra ^a   Völpel, Heiko ^g   Pötzsch, Bernd ^h   Luz, Matthias ⁱ  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

^d OTTO VON GUERICKE UNIVERSITY   (Germany)

^e Centeon Pharma GmbH   (Germany)

^f JUSTUS LIEBIG UNIVERSITY   (Germany)

^g Chiron Behring GmbH & Co   (Germany)

^h KERCKHOFF HEART CENTER   (Germany)

ⁱ SANOFI   (France)

Author keywords

Heparin; Hirudin; Lepirudin; Platelets; Thrombocytopenia

Indexed keywords

HEPARIN; LEPIRUDIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIMB AMPUTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARTIAL THROMBOPLASTIN TIME; PATIENT COMPLIANCE; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOEMBOLISM;

EID: 0033543081     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.6.587     Document Type: Article

References (20)

1. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost. 1998;79:1-7.
2. Greinacher A. Antigen generation in heparin-associated thrombocytopenia: the nonimmunologic type and the immunologic type are closely linked in their pathogenesis. Semin Thromb Hemost. 1995;21:106-116.
3. King DJ, Kelton JG. Heparin-associated thrombocytopenia. Ann Intern Med. 1984;100:535-540.
4. Warkentin TE, Kelton JG. Heparin-induced thrombocytopenia. Annu Rev Med. 1989;40:31-44.
5. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101:502-507.
6. Stringer KA, Lindenfield J. Hirudins: antithrombin anticoagulants. Ann Pharmacother. 1992;26:1535-1540.
7. Schiele F, Lindgaerde F, Eriksson H, Bassand J-P, Wallmark A, Hansson P-O, Grollier G, Sjo M, Moia M, Camez A, Smyth V, Walker M, for the International Multicentre Hirudin Study Group. Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multi-centre prospective dose-ranging randomized trial. Thromb Haemost. 1997;77:834-838.
8. Weitz JI, Hudoba M, Massel D, Marganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin Ill-independent inhibitors. J Clin Invest. 1990;86:385-391.
9. Chong BH, Murray B, Berndt MC, Dunlop LC, Brighton T, Chesterman CN. Plasma P-selectin is increased in thrombotic consumptive platelet disorders. Blood. 1994;83:1535-1541.
10. Warkentin TE, Hay ward CP, Boshkov LK, Santos AV, Sheppard JA, Bode AP, Kelton JG. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood. 1994;84:3691-3699.
11. Greinacher A, Völpel H, Janssens U, Hach-Wunderle V, Kemkes-Matthes B, Eichler P, Mueller-Velten HG, Pötzsch B, for the HAT investigators group. Recombinant hirudin (lepirudin) provides effective and safe anticoagulation in patients with heparin-induced thrombocytopenia type II: a prospective study. Circulation. 1999;99:73-80.
12. Greinacher A, Michels I, Kiefel V, Mueller-Eckhardt C. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost. 1991;66:734-736.
13. Carlsson LE, Santoso S, Baurichter G, Kroll H, Papenberg S, Eichler P, Westerdaal NAC, Kiefel V, van de Winkel JGJ, Greinacher A. Heparin-induced thrombocytopenia: new insights into the impact of the FcγRIIa-131R-H polymorphism. Blood. 1998;92:1526-1531.
14. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: Wiley; 1980.
15. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic Research: Principles and Quantitative Methods. Belmont, Calif: Lifetime Learning Publications; 1982.
16. Ulm K, Schmoor C, Sauerbrei W, Kemmler G, Aydemir Ü, Müller B, Schumacher M. Strategien zur Auswertung einer Therapiestudie mit der Überlebenszeit als Zielkriterium (Strategies for evaluation of a therapeutic trial with survival time as end point). Biometrie Informatik Med biol. 1989;20:171-205.
17. Nand S, Wong W, Yuen B, Yetter A, Schmulbach E, Gross-Fisher S. Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Am J Hematol. 1997;56:12-16.
18. AbuRahma AF, Boland JP, Witsberger T. Diagnostic and therapeutic strategies of white clot syndrome. Am J Surg. 1991;162:175-179.
19. Magnani HN. Orgaran (danaparoid sodium) use in the syndrome of heparin-induced thrombocytopenia: proceedings of a workshop held in London, 1996 Nov 1. Platelets. 1997;8:74-81.
20. Wilde MI, Markham A. Danaparoid: a review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia. Drugs. 1997;54:903-924.